Division of Pfizer Inc.
Latest From Sugen Inc.
The week's round-up includes a new CEO at Synthorx Inc., new sales executives at Aerie Pharmaceuticals and board appointments at BTG, Pertinax Pharma, Realm Therapeutics, Breath Therapeutics, iOnctura, NBE Therapeutics and Inflazome.
Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.
The convergence of maturing technology, growing industry demand for combination therapy, and regulatory innovation have given rise to Blueprint Medicines, a pure-play kinase specialist that aspires to become a US-focused cancer company.
The targeted cancer therapeutics venture Xcovery has received a major investment from China's Betta Pharma as part of a licensing deal for a clinical stage oncology asset.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Stephen Evans-Freke, CEO
Bruce E MacMillan, VP, General Counsel & Corp. Secretary
Gerald McMahon, VP, Drug Discovery
Sara A Courtneidge, PhD, SVP, Research
- Contact Info
Phone: (650) 553-8300
230 East Grand Ave.
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.